Duke Cancer Institute Duke University Medical Center Durham, North Carolina
In 1972, the Duke Comprehensive Cancer Center, now known as the Duke Cancer Institute (DCI), was established and designated by NCI as one of the first comprehensive cancer centers. The DCI serves as the focus for all of Duke University’s activities in cancer. It is a single entity that integrates and aligns patient care and research with the goals of improving patient outcomes, decreasing the burden of cancer and accelerating scientific progress.
More than 300 clinicians and researchers within the DCI represent 12 basic and clinical departments. These researchers are dedicated to a broad spectrum of cancer research and the translation of that research into the latest in patient care.
The Institute comprises 11 disease-site and 9 approached-based research programs representing areas of specialized expertise and focus on basic, translational, clinical, and population research. The disease-site programs include Brain Tumor, Breast, Gynecologic, Thoracic, Gastrointestinal, Hematologic Malignancies, Prostate, Head and Neck, Endocrine Neoplasias, Melanoma, Sarcoma, and Pediatric cancers. The approached-based programs include Tumor Biology, Cancer Genetics and Genomics, Cancer Control and Population Sciences, Neuro-Oncology, Women’s Cancer, Hematologic Malignancies and Cellular Therapies, Solid Tumor Therapeutics, Radiation Oncology and Imaging, and Developmental Therapeutics.
DCI researchers bring a diversity of knowledge which has led to a number of significant collaborations on campus and beyond. In one notable partnership at Duke, the DCI is collaborating with the Nicholas School of the Environment to unravel the relationship between genes and the environment in order to understand better why some people develop disease and why some remain unaffected when exposed to the same environmental factors.
In addition, DCI has developed global partnerships in Singapore, India, and China. In 2010, Duke University and the National University of Singapore (NUS) agreed to expand the growth of the Duke-NUS Graduate Medical School. The venture continues to strengthen Duke’s contribution as a research and educational partner and positions Singapore as a global hub of biomedical expertise.
More than 50,000 individuals with cancer receive treatment at the Duke Cancer Institute each year. Patients treated at the Duke Cancer Institute represent virtually every state in the nation and every county in North Carolina. More than 60 percent of new patients are referred to Duke for their initial treatment.
The Duke Oncology Network provides an array of oncology related services in a regional network of 20 community cancer programs in North Carolina and the southeast. Through the Network, the DCI offers patients and their providers access to state-of-the-art research and education programs and provides new cancer education initiatives for patients in rural areas. These community collaborations also provide patients and their providers with greater access to the most advanced treatments and clinical trials.
* This profile was provided by the Duke Cancer Institute.